Background: Noninvasive evaluation of the status of cerebral arteriole perfusion remains a practical challenge in murine stroke models, because conventional magnetic resonance imaging (MRI) is no longer capable of capturing these very small vessels. Purpose: To investigate the feasibility of ultrasmall superparamagnetic iron oxide particles (USPIO)-based susceptibility weighted imaging (SWI)-MRI (USPIO-SWI) and T2* map-MRI (USPIO-T2* map) for monitoring angiographic perfusion in stroke rats. Study Type: A preclinical randomized controlled trial. Animal Model: Normal rats (N = 9), embolic middle cerebral artery occlusion (eMCAO) rats (N = 66). Field Strength/Sequence: 7 T; T2* map (multigradient echo), SWI (3D gradient echo). Assessment: Experiment 1: To develop a method for angiographic reperfusion evaluation with USPIO-SWI. Normal rats were used to optimize the USPIO dosage (5.6, 16.8, and 56 mg/kg ferumoxytol) as well as scan time points for cerebral arterioles. Contrast-to-noise ratio (CNR) was measured. Stroke rats were further used and the number of visual cortical vessels were counted. Experiment 2: To examine whether fingolimod (lymphocytes inhibitor) enhances the action of tissue plasminogen activator (tPA) in eMCAO rats on cerebral angiographic reperfusion. Statistical Tests: Mann-Whitney test and two way-ANOVA were used. P < 0.05 was considered statistically significant.Results: CNR values of cerebral cortical penetrating arteries in normal rats were significantly increased to 4.4 AE 0.5 (5.6 mg/kg), 6.1 AE 0.5 (16.8 mg/kg), and 3.4 AE 0.9 (56 mg/kg) after USPIO injection. The number of visual cortical vessels on USPIO-SWI images in ischemic regions was significantly less than in control regions (5 AE 2 vs. 56 AE 20) of eMCAO rats. Compared with eMCAO rats who received tPA only, eMCAO rats who received the combination of fingolimod and tPA exhibited significantly higher proportion of complete angiographic reperfusion (69% vs. 17%). Data Conclusion: This study supports the feasibility of angiographic perfusion evaluation with USPIO-SWI in stroke rats. Level of Evidence: 2 Technical Efficacy Stage: 1